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Metastasis contributes to >90% of cancer-associated mortality. Though primary tumors
can be removed by surgical resection or chemo/radiotherapy, metastatic disease is a great
challenge to treatment due to its systemic nature. As metastatic “seeds,” circulating
tumor cells (CTCs) are believed to be responsible for dissemination from a primary tumor
to anatomically distant organs. Despite the possibility of physical trapping of CTCs in
microvessels, recent advances have provided insights into the involvement of a variety
of adhesion molecules on CTCs. Such adhesion molecules facilitate direct interaction
with the endothelium in specific tissues or indirectly through leukocytes. Importantly,
significant progress has been made in understanding how these receptors confer
enhanced invasion and survival advantage during hematogenous circulation of CTCs
through recruitment of macrophages, neutrophils, platelets, and other cells. This review
highlights the identification of novel adhesion molecules and how blocking their function
can compromise successful seeding and colonization of CTCs in new microenvironment.
Encouraged by existing diagnostic tools to identify and isolate CTCs, strategic targeting of
these adhesion molecules to deliver conventional chemotherapeutics or novel apoptotic
signals is discussed for the neutralization of CTCs in the circulation.
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INTRODUCTION
Circulating tumor cells (CTCs) are cells that leave a primary
tumor and circulate in the blood. More than a century ago the
Australian physician Thomas Ashworth first observed CTCs in
the blood of a patient with metastatic cancer. He hypothesized
that “the cancer itself being seen in the blood may tend to throw
some light upon the mode of origin of multiple tumors existing
in the same person.” In the past decade, advancing technologies to
detect and isolate CTCs have provided unique fluid biopsy infor-
mation for prognosis, management of chemotherapy dosing and
timing as well as monitoring the development of drug resistance
over time (Nagrath et al., 2007; Lowes et al., 2011; Scher et al.,
2011). Driven by these technologies, numerous clinical studies
performed for breast, colon, prostate, and other epithelial can-
cers establish a clear connection between average CTC counts and
overall survival rate before and during treatment (Cristofanilli
et al., 2004, 2005; Hou et al., 2009; Criscitiello et al., 2010; Yalcin
et al., 2010; Danila et al., 2011; Lianidou and Markou, 2011).
In contrast to the rapid development of tools for CTC detec-
tion and isolation, effective therapies that directly remove CTCs
from the blood circulation are still underexplored. This is proba-
bly attributable to our limited understanding of the heterogeneity
of CTCs: in most studies, CTCs are defined as being positive for
epithelial cell adhesion molecule (EpCAM+) and cytokeratin 8,
18, or 19 (CK+) and negative for CD45 (CD45−) (Allard et al.,
2004). However, almost a third of patients with advanced breast,
colorectal, and prostate cancers have CTCs that do not meet these
criteria (Coumans et al., 2010). Despite the heterogeneity of CTC
markers, some studies have shown that cancer stem cell (CSC)
or stem-like cell (CSC-like) markers are frequently expressed by
CTCs (Aktas et al., 2009; Theodoropoulos et al., 2010; Iinuma
et al., 2011; Toloudi et al., 2011; Kasimir-Bauer et al., 2012; Wang
et al., 2012). Such features are especially relevant for targeting
CTCs as CSCs are believed to represent a subpopulation of cancer
cells that drive the growth and progression of metastatic cancers
(Ghiaur et al., 2012; Vermeulen et al., 2012).
The presence of CTCs in the circulation can in part explain
a clinical observation that the removal of a primary tumor is
often followed with distant metastasis and/or local recurrence.
For example, it was estimated that 20–50% patients first diag-
nosed with primary breast cancer eventually developedmetastatic
disease in the past (Lu et al., 2009). In the case of hepatocellu-
lar carcinoma (HCC), liver transplantation is the best treatment
for early-stage patients. Unfortunately, every year around 10% of
recipients develop post-transplant HCC recurrence, which leads
to death in almost all patients (Toso et al., 2011). To understand
themolecular mechanism, Kim and colleagues developed a tumor
self-seeding mouse model whereby the local recurrence mediated
by CTCs was investigated using human colorectal, melanoma,
and breast cancer cells. They found that tumor-derived IL-6
and IL-8 served as CTC attractants whereas the seeder CTCs
highly expressed invasion-associated genes (MMP1, FSCN1, and
CXCL1) to promote infiltration (Kim et al., 2009). This find-
ing highlights a highly orchestrated process of local recurrence
mediated by CTCs.
CTCs play a predominant role in the metastases to distant
organs. In the blood circulation, CTCs are subject to a multitude
of stresses including anchorage-dependent survival signaling,
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immuno-surveilance, and shear stress. For example, CTCs are
deprived of integrin-dependent adhesion to extracellular matrix
(ECM) components in comparison to nontransformed cells.
Whereas such loss of anchorage induces apoptosis (anoikis) in
normal cell types, CTCs are particularly resistant to anoikis
by promoting PI3K/Akt proliferation signaling and expression
of anti-apoptotic proteins such as BCL2 (Frisch and Ruoslahti,
1997; Guo and Giancotti, 2004). Notably, numerous research
has demonstrated that CTCs do not mobilize in the circulation
alone. Instead, through heterotypic interactions with endothelial
cells and different types of haemopotoeic cells, CTCs acquire the
potential to metastasize to distant organs (Figure 1). Therefore,
such receptor-mediated adhesion can provide a unique oppor-
tunity for neutralizing CTCs either through the blockade of
receptors or receptor-targeted drug delivery.
THE BIOLOGY OF SELECTIN-MEDIATED HEMATOGENOUS
METASTASIS
Selectins are transmembrane glycoproteins which were initially
found to bind specific glycoproteins on leukocytes. Three struc-
turally related adhesion molecules, L-, E-, and P-selectin are
composed of an N-terminal C-type lectin domain which con-
fers specific, Ca2+-dependent carbohydrate-binding activity. It is
followed by an epidermal growth factor (EGF)-like domain, a
variable number of short consensus repeats domains (2, 6, and
9 for L-, E-, and P-selectin, respectively), a single-pass trans-
membrane domain and a short intracellular C-terminal tail (Ley,
2003). Despite structural similarity, the three selectins have dis-
tinct tissue-specific expression and binding kinetics. L-selectin
is constitutively expressed on the surface of almost all types
of leukocytes and is cleaved from the cell surface upon activa-
tion with a variety of cytokines and chemokines (Grailer et al.,
2009). In contrast, the expression of E- and P-selectin is inducible
on vascular endothelial cells during inflammation. Whereas
E-selectin depends on de novo mRNA synthesis, P-selectin is
stored in Weibel-Palade bodies of endothelial cells. Additionally,
platelets express P-selectin which translocates from α-granules
upon platelet activation (Larsen et al., 1992).
The role of selectins in mediating the rolling and trafficking
of neutrophils and monocytes to inflammation sites has been
well studied. More recently, it has been proposed that CTCs
adopt similar strategies to facilitate their initial entrapment in
the vessels and subsequent extravasation. Köhler and colleagues
provided the first in vivo evidence that E- and P-selectin are essen-
tial for colorectal cancer metastasis. They generated a transgenic
immuno-compromised mouse with E- and P-selectin doubly
knocked out. Compared to wild-type mice, the double knockout
mice with subcutaneously implanted colon cancer cells showed
lung metastases reduced in number by 84% (Kohler et al., 2010).
In agreement with earlier in vitro studies, a model was proposed
in which the sialylated fucosylated glycans decorated on trans-
membrane proteins or specific lipids of CTCs mediate the rolling
and adhesion to selectin-expressing endothelial cells. The role
of selectin ligands in mediating the hematogenous metastasis of
CTCs has been reviewed extensively elsewhere (Konstantopoulos
and Thomas, 2009; Geng et al., 2012). However, this section
focuses on therapeutic interventions of selectin binding that have
been explored for the prevention of metastasis.
FIGURE 1 | The heterotypic cell interactions between CTCs and
haemopotoeic cells in the circulation. Macrophages interact with CTCs
via α4-integrin-VCAM-1 ligation and transmit anti-apoptotic signal such as
TRAIL to CTCs. In contrast, certain CTCs deficient for selectin ligands
can roll and adhere to endothelial cells through heterotypic interaction
with neutrophils. This interaction is mediated by β2-integrin and
ICAM-1 expressed on neutrophils and CTCs, respectively. Additionally,
CTCs can locally induce platelet aggregation. The deposition of platelets
on CTCs prevents the damage caused by shear stress and
immuno-surveillance.
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CARBOHYDRATE-BASED INHIBITORS
Given that all three selectins recognize sialylated fucosylated
glycans such as sLex, the sLex analogs have been shown to signif-
icantly prevent neutrophil accumulation and myocardial necrosis
after ischemia and reperfusion in animal models (Buerke et al.,
1994; Lefer et al., 1994; Zacharowski et al., 1999). This implies
that the same analogs may be potent inhibitors for reducing
CTC adhesion to endothelium. Shirota and colleagues investi-
gated the inhibitory effect of a sLex analog, GSC-150 on hepatic
metastasis of human colon carcinoma in nude mice. They found
that liver metastases were significantly attenuated when cancer
cells were co-administered with GSC-150 (Shirota et al., 2001).
In addition to sLex analogs, novel disaccharides have been gen-
erated which function as competitive substrate inhibitors for
glycotransferases involved in the synthesis of sLex. To this end,
a disaccharide compound was able to inhibit sLex formation in
human monocytic leukemia cells, U937. Its therapeutic effect
was further studied in Lewis lung carcinoma in vivo where the
experimental metastasis was significantly reduced through the
decreased expression of sLex (Brown et al., 2009). Nevertheless,
strategies to abrogate sLex-selectin interactionmust be considered
carefully. Given the turnover rate of selectins or glycotrans-
ferases, such carbohydrates may not have a long-lasting inhibitory
effect. Moreover, as sLex is essential for directing neutrophils and
lymphocytes to inflamed tissues, the chronic exposure to sLex
analogs or metabolic inhibitors can interfere with the normal
inflammatory response. Therefore, investigations on the cellu-
lar sLex synthesis that differentiate CTCs from leukocytes may
provide more specific targeting of CTCs while reducing side
effects.
GENE SILENCING OF FUCOSYLTRANSFERASES IN CTCs
As the key determinants of selectin ligands, sLex and sLea
are synthesized in the Golgi compartments by sequential
actions of N-acetylglucosaminyl-, galactosyl-, sialyl-, and fucosyl-
transferases. Of note is the terminal step of transferring fucose to
N-acetylglucosamine catalyzed by a family of fucosyltransferase
genes (Hennet, 2002). At least nine FUT genes have been iden-
tified in the human genome among which FUT3, 4, 6, and 7
have been well characterized. They are redundant in the syn-
thesis of sialyl lewis carbohydrates but display cell type-specific
expression. FUT4 and FUT7 are mainly expressed in blood cell
lineages and play a key role in the selectin ligand-mediated migra-
tion of leukocytes during the inflammatory response (Weninger
et al., 2000). In contrast, FUT3 and FUT6 are more associ-
ated with the progression of cancers, including breast (Matsuura
et al., 1998; Ding and Zheng, 2004), prostate (Barthel et al.,
2008), lung (Ogawa et al., 1996), liver (Wang et al., 2003),
and gastric cancer (Petretti et al., 1999). To exploit the thera-
peutic potential of targeting fucosyltransferases, our laboratory
first confirmed that hematopoietic cell lines (HL60 and KG1a)
predominantly express FUT4 and FUT7 whereas prostate can-
cer cell line MDA PCa2b mainly expresses FUT3. Next, siRNA
against FUT3 reduced sLex expression on prostate cancer cells and
significantly inhibited cell rolling and adhesion to a E-selectin-
functionalized surface under physiological flow. In addition, the
siRNA was able to impair cell growth which may not be directly
associated with sLex. In fact, two recent studies revealed that
the overexpression of FUT4 and FUT6 promoted cell growth by
elevating intracellular Akt phosphorylation and suppressing the
cyclin-dependent kinase inhibitor p21 in epidermoid carcinoma
and HCC cells, respectively, (Yang et al., 2010; Guo et al., 2012).
Therefore, silencing FUTs via siRNA can simultaneously inhibit
the adhesion and clonal expansion of CTCs in the blood circu-
lation. To apply this strategy in vivo, P-selectin-based liposome
nanoparticles recently developed in our laboratory can be used
to encapsulate siRNAs against FUTs (Huang and King, 2009).
Although P-selectin recognizes both circulating leukocytes and
CTCs, siRNAs against FUTs exclusively expressed in CTCs provide
additional targeting specificity.
THERAPEUTIC ABROGATION OF CTC-HEMATOPOIETIC
CELL INTERACTION
It is estimated that less than 0.01% of CTCs shed from a primary
tumor can survive to produce clinically relevant metastases (Joyce
and Pollard, 2009). This suggests that the process of metastasis
by CTCs is largely inefficient. Whereas the mechanisms underly-
ing such high rates of attrition remain poorly understood, recent
studies identified two important cell adhesion molecules involved
in the physical interactions of CTCs with hematopoietic cells:
vascular cell adhesion molecule-1 (VCAM-1) and intercellular
adhesionmolecule-1 (ICAM-1). Such interactions facilitate CTCs
in several aspects: (1) survival in the circulation, (2) initial arrest
and subsequent extravasation, and (3) eventual growth into overt
metastasis (Chambers et al., 2002).
The transmembrane protein VCAM-1 was originally thought
to be presented exclusively on endothelial cells in response to
tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1)
during inflammation (Coussens and Werb, 2002). It binds to
the leukocyte integrins α4β1 and α4β7 on circulating mono-
cytes, granulocytes, and lymphocytes (Osborn et al., 1989; Elices
et al., 1990). However, aberrant expression of VCAM-1 was
found to be one of 18 signature genes associated with lung
metastasis of breast cancer in both experimental mouse mod-
els and patients (Minn et al., 2005). Chen and colleagues found
that VCAM-1 on breast cancer CTCs tethered to metastasis-
associated macrophages which express α4-integrins. Clustering of
VCAM-1 onCTCs induces Akt activation and protects CTCs from
proapoptotic cytokines such as TNF-related apoptosis-inducing
ligand (TRAIL). Notably, either silencing VCAM-1 expression
by siRNA or blocking antibody against α4-integrins abolished
the pro-survival effect of VCAM-1 (Chen et al., 2011). In addi-
tion, VCAM-1 was also recently found to be associated with bone
metastasis in breast cancer. Prior to this study, a bone-metastatic
gene signature including CXCR4, IL11, CTGF, MMP1, and OPN
was identified through the reiterative selection of human breast
cancer cells MDA-MB-231 in immuno-compromised mice (Kang
et al., 2003). However, by studying a subpopulation of MDA-MB-
231 which experienced a long dormancy prior to bone metastasis,
Lu and colleagues discovered that the aberrant expression of
VCAM-1 engaged α4-integrins on monocytic osteoclast progen-
itors to promote the local osteolytic activity in bone (Lu et al.,
2011). This mouse study was further corroborated by comparing
VCAM-1 levels between clinical early and late recurrences of bone
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metastases. Higher VCAM-1 was significantly associated with
early relapse (Wang et al., 2005).
Like VCAM-1, ICAM-1 is another cell surface glycoprotein
which is typically expressed on endothelial cells in response
to TNF-α or IL-1 in inflammation. However, the constitutive
expression of ICAM-1 on CTCs was found to promote tumor
cell transendothelial migration in melanoma (Huh et al., 2010),
pancreatic (Roland et al., 2010), and breast cancers (Wu et al.,
2001). To understand this mechanism, in vitro biophysical studies
demonstrated that under physiological shear stress ICAM-1 on
melanoma CTCs promotes the heterotypic interaction with neu-
trophils by engaging β2-integrins (CD11a and CD11b) (Hoskins
andDong, 2006; Liang et al., 2008). Moreover, as neutrophils have
selectin ligands, such heterotypic interaction facilitates the adhe-
sion and extravasation of melanoma CTCs which otherwise bind
inefficiently to the endothelium (Slattery and Dong, 2003; Liang
et al., 2005). Later, our laboratory studied the physical mech-
anisms of retinoblastoma metastasis. Whereas human RB cell
lines RB143 and WERI-Rb27 do not express E-selectin ligands,
they can be recruited to an E-selectin-coated surface through
attachment to activated neutrophils. This interaction is alsomedi-
ated by ICAM-1: β2-integrin (Geng et al., 2010). To test the
involvement of this heterotypic interaction in vivo, Jin Huh and
colleagues compared the lung metastases of human melanoma
cells injected alone or in combination with human neutrophils
(Huh et al., 2010). They found that human neutrophils enhanced
CTCs retention in the lung by three-fold. To dissect the molec-
ular mechanism, the cytokine interleukin-8 (IL-8) was found to
be a key determinant expressed by melanoma cells to attract
neutrophils. IL-8 secretion increased β2-integrin levels on neu-
trophils and heterotypic aggregation between ICAM-1-positive
CTCs and neutrophils. Importantly, siRNA against IL-8 impaired
transendothelial migration and lung metastasis by ∼50%. In
addition to targeting IL-8 as a therapeutic approach, it is possi-
ble that blocking antibodies against ICAM-1 or β2-integrins may
be also effective (Rosette et al., 2005).
PLATELETS AGGRAVATE CTC METASTASIS
Platelets are anuclear cytoplasmic bodies released from
megakaryocytes in the bone marrow. It is estimated that
one liter of blood contains about 400 billion circulating platelets.
The primary role of platelets is to maintain haemostasis. This
is initiated via platelet activation which results in adhesion and
release of a multitude of bioactive factors from platelet granules.
In addition to haemostatic regulation, platelets have long been
believed to play a critical role in cancer metastasis through the
enhancement of CTC survival and adhesion to the endothelium
in the circulation. The involvement of platelets in cancer was first
recorded in the mid-nineteenth century by the French clinician
Armand Trousseau. He diagnosed patients with migratory
thrombophlebitis caused by an occult visceral carcinoma (Gupta
andMassague, 2004). In fact, preclinical studies in genetic knock-
out mice provide evidence that upon immediate entry into the
circulation, tissue factor highly expressed by CTCs can signal
downstream through FVIIa and FXa to activate a coagulation
cascade leading to thrombin generation, fibrin deposition, and
platelet aggregation around CTCs (Camerer et al., 2004; Kasthuri
et al., 2009; Liu et al., 2011). Such a “platelet cloak” is known to
initially trap tumor cells in microvessels (Borsig et al., 2001).
Several mechanisms of platelets in promoting CTC survival
have been proposed based on preclinical experiments in mice
using a variety of mouse and human carcinoma cell lines.
Aggregation of platelets around CTCs protect against immune-
mediated clearance of CTCs largely mediated by natural killer
(NK) cells. The potential of CTCs to induce platelet aggrega-
tion correlates with their enhancedmetastatic potential. Bernhard
Nieswandt and colleagues demonstrated for the first time that
platelets directly impair NK lysis of tumor cells in vitro and
in vivo. In a mouse model of experimental metastasis, they found
that tumor seeding in the lung was reduced when platelets were
depleted from the host (Nieswandt et al., 1999). Further stud-
ies reveal that CTC evasion of NK cells is not merely attributed
to physical shielding of platelets. NK cell activity is guided by
the principles of “missing-self” and “induced-self,” which imply
that cells lacking expression of MHC class I (missing-self) and/or
a stress-induced expression of ligands for activating NK recep-
tors (induced-self) are preferentially recognized and eliminated
(Moretta and Moretta, 2004; Lanier, 2005). While CTCs are often
associated with lack of MHC class I, platelets can disrupt “miss-
ing self” recognition of NK cells by grafting MHC I class onto
CTCs (Placke et al., 2012). Furthermore, platelet-derived trans-
forming growth factor β (TGF-β) can downregualte the activating
immunoreceptor NK group 2, member D (NKG2D) on NK cells
(Kopp et al., 2009).
THERAPEUTIC INTERVENTION OF PLATELET ADHESION TO CTCs
As the blood clotting pathway contributes to platelet adhesion to
CTCs, a variety of anticoagulation agents have been tested either
alone or together with conventional cancer drugs in preclinical
mouse models. Using an experimental metastasis mouse model,
Amirkhosravi and colleagues found that the intravenous injec-
tion of recombinant mouse tissue factor pathway inhibitor (TFPI)
immediately before inoculation of tumor cells reduced metastasis
by 83% (Amirkhosravi et al., 2002, 2007). Similarly, Cilostazol,
a selective inhibitor of phosphodiesterase 3 with anticoagulatory
and profibrinolytic effects completely abolished the complex for-
mation of 4T1 tumor cells in the presence of activated platelets
in vitro. In a spontaneous model of mouse 4T1 breast cancer,
the injection of Cilostazol six hours before tumor inoculation
reduced pulmonary metastasis by 55%. As platelet aggregation
and adhesion to CTCs enhance their survival in the blood cir-
culation, abrogation of the coagulation cascade renders CTCs
susceptible to cancer drugs. Wenzel and colleagues invented dual
liposomes simultaneously containing the hemostatic inhibitor
dipyridamole and the anticancer drug perifosine. The liposomes
caused a 90% reduction in the number of lung metastases in a
mouse experimental metastasis model (Wenzel et al., 2010).
Despite the fact that anticoagulants hold promise for the pre-
vention of metastasis, they may impair the normal hemostatic
function of platelets in the presence of bleeding. Platelet interven-
tion therapies against metastasis must exhibit certain specificity
for tumor cell-platelet interactions. Therefore, direct inhibition
of platelet adhesion to CTCs may minimize the cardiovascular
side effect of anticoagulants. To this goal, heparin and chemically
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modified heparins have been shown to attenuate the metas-
tasis of human colon carcinoma in a mouse xenograft model
(Koenig et al., 1998; Stevenson et al., 2005; Hostettler et al.,
2007). The anti-metastatic effect of heparin was initially believed
to associate with its anticoagulant activity. Later it was found
that competitive binding of heparin to P-selectin on activated
platelets abolishes interaction with P-selectin ligands such as sia-
lylated fucosylated mucins expressed on human colon carcinoma
cells (Wei et al., 2004; Stevenson et al., 2005; Hostettler et al.,
2007; Lee et al., 2008). As the anticoagulant activity of heparin
is undesirable in the context of blocking CTC-platelet interac-
tions, polysaccharides isolated from certain sea plants and fungi
have shown enhanced inhibition of P-selectin binding without
anticoagulant effect. A fucosylated chondroitin sulfate (FucCS)
from sea cucumber is 4–8 fold more potent than heparin in
the inhibition of LS180 carcinoma cell attachment to immo-
bilized P- and L-selectin. Moreover, administration of FucCS
30min prior to mouse colon carcinoma MC-38 injection is asso-
ciated with 2-fold CTC-platelet aggregates than heparin in the
mouse lung. Long-term experiment reveals that FuCS signifi-
cantly reduced lung metastatic foci by 80% compared to saline
control (Borsig et al., 2007).
THERAPEUTIC BLOCKAGE OF PLATELET SIGNALING TO CTCs
Certain CTCs express epithelial markers such as EpCAM and
cytokeratins, suggesting that the epithelial-mesenchymal transi-
tion (EMT) is not necessarily required for CTCs to access the
blood circulation. Instead, a transient contact between platelets
and CTCs in the blood circulation is sufficient to induce an
EMT gene signature and invasive behavior primarily through
the platelet-secreted transforming growth factor-β1 (TGF-β1)
(Labelle et al., 2011). Recently, a small molecule inhibitor, SD-
208, has been shown to block the TGF-β receptor I kinase
(TβRI) activity. SD-208 successfully prevented the development
of TGF-β-induced bone metastases and decreased the progres-
sion of established osteolytic lesions in a melanoma mouse
model (Mohammad et al., 2011). Therefore, SD-208 possi-
bly represents a viable therapeutic to inhibit platelet-derived
TGF-β signaling. In addition to TGF-β, platelet α-granules store
abundant proangiogenic factors including vascular endothelial
growth factor (VEGF), basic fibroblast growth factor (bFGF),
EGF, platelet-derived growth factor (PDGF) and insulin-like
growth factor-1 and -2 (IGF-1 and -2) (Sierko and Wojtukiewicz,
2007). Given that inhibitors for the proangiogenic factors or
their counter-receptors are available as cancer drugs in the treat-
ment of solid tumors (Roberts et al., 2005; Moreira et al., 2007;
Weroha and Haluska, 2008), it is possible that such inhibitors
can be used as adjuvant therapies in the context of targeting
CTCs.
NOVEL SELECTIN-BASED TARGETING DRUG DELIVERY
TO CTCs
Over the past several years, our laboratory has developed
a biomimetic approach to isolate CTCs using a selectin-
immobilized microtube device (Hughes and King, 2010; Hughes
et al., 2012a,b). Two factors are responsible for the efficient cap-
ture of CTCs by this device. First, the ability of selectins to
mediate the rapid tethering and rolling of leukocytes or CTCs
under shear is attributed to the fast kinetics between selectins
and selectin ligands (Lawrence and Springer, 1991; Wild et al.,
2001). The fact that cells can be enriched under flow conditions
significantly enhances the sample processing rate. Second, the
microtube allows for the margination of CTCs toward the wall
to interact with immobilized selectins. This margination effect
has been well characterized when leukocytes circulate in a flow-
dependent interaction with red blood cells (Bagge et al., 1983;
Goldsmith and Spain, 1984; Iadocicco et al., 2002).
Inspired by isolating CTCs under flow conditions, we trans-
lated the device to a unique drug delivery platform whereby
the immobilization of drug molecules on the surface creates a
high localized concentration. One device immobilizes E-selectin-
conjugated liposomes onto the surface of a blood-compatible
microrenathane (MRE) tube. After encapsulating doxorubicin
(DOX), the liposomes could specifically capture cells from the
flow and efficiently deliver DOX into adherent cells. Moreover,
a halloysite nanotube (HNT)-coated surface further enhanced
the targeting and killing of cancer cells (Figures 2A,B), which
was attributed to the increased surface area for both E-selectin
and DOX.
To provide more specificity to CTCs, two additional
approaches have been pursued by our laboratory. One approach
was to functionalize the microtube surface with both E-selectin
and antibodies against epithelial markers such as EpCAM. Such
additional antibodies were able to discriminate between leuko-
cytes and CTCs when cells roll on the surface (Hughes et al.,
2012a). The second approach was to replace DOX with molecules
that are tumor-specific, such as TRAIL. TRAIL holds promise as
a tumor-specific therapeutic as it selectively induces an apop-
totic signal by binding to death receptors on the cell surface
(Koschny et al., 2007;Wang, 2008). To this end, our lab developed
a death receptor-mediated apoptosis device to deliver apopto-
sis signal to captured CTCs (Figure 3A). Notably, with TRAIL
and E-selectin on the surface, one hour of rolling exposure was
sufficient to kill 30% of leukemia cells (HL60) whereas the viabil-
ity of normal mononuclear cells was not affected (Figures 3B,C)
(Rana et al., 2009, 2012).
CONCLUDING REMARKS
In haematogenous metastasis, a primary tumor sheds CTCs into
the blood circulation which comprise a population of carcinoma
cells that can exhibit CSC or CSC-like features. Two hypothe-
ses have been proposed regarding how CTCs establish the initial
contact with endothelial cells prior to metastasis. The physical
trapping hypothesis is based on the fact that the luminal diameter
of capillaries is ∼8μm while the diameter of CTCs ranges from
20 to 30μm. Thus, CTCs can be simply mechanically trapped in
the capillary bed during their first pass through the circulation
(Valastyan and Weinberg, 2011). However, the findings that cer-
tain CTCs display organ-specific tropism (e.g., bone metastases
in breast and prostate cancer) challenge this hypothesis (Kang
et al., 2003; Barthel et al., 2008). In fact, by displaying selectin
ligands on their surface, CTCs in certain cancers acquire the
ability to roll and adhere to the endothelium and subsequently
exit from the circulation. The identification of selectin-dependent
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FIGURE 2 | E-selectin liposomal and nanotube-targeted delivery of doxorubicin to CTCs. (A) Schematic of E-selectin-coated liposome encapsulating
doxorubicin (DOX). (B) Schematic of a microtube device for delivering DOX to captured CTCs.
FIGURE 3 | Delivery of apoptotic signal to rolling cancer cells.
(A) Schematic of a biomimetic device for inducing apoptosis in CTCs using
E-selectin and TRAIL. (B) HL60 leukemic cells are eliminated by
approximately 30% following perfusion through a device coated with both
E-selectin and TRAIL. (C) Viability of normal mononuclear cells is not affected
by the TRAIL-coating, confirming the specificity of TRAIL for malignant cells.
(A–C) are reproduced from Rana et al., 2009 with permission. Rana et al.,
2009 is Copyright 2008 Wiley Periodicals, Inc.).
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metastasis has made it possible to develop a range of antagonists
against selectins or selectin ligands. Such antagonists have proven
efficient in reducing experimental metastases inmanymouse can-
cer models. However, they may impair the selectin-dependent
trafficking of leukocytes to inflamed areas during the normal
inflammatory response. The gene silencing of specific FUTs may
confer specificity to CTCs as different FUTs have been shown to
differentially express in CTCs versus leukocytes (Yin et al., 2010).
Nevertheless, the CTC-endothelium interaction alone is not suf-
ficient for CTCs to overcome damages incurred by hemodynamic
shear forces and immuno-surveillance. The survival of CTCs
in the blood circulation also depends on the interactions with
haemopoetic cells such asmacrophages, neutrophils, and platelets
which require distinct adhesion receptors. Though the abrogation
of individual adhesion receptors has shown promising results in
a variety of mouse cancer models, it may be clinically relevant to
develop a cocktail therapy which simultaneously targets multiple
interactions between CTCs and other cell types.
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